Cagrilintide (5 mg vial + 2 mL bacteriostatic water reconstitution) gives a concentration of 2.5 mg/mL (2500 mcg/mL).
On a U-100 insulin syringe (100 units = 1 mL):
• 1 unit = 0.01 mL = 25 mcg (0.025 mg) of cagrilintide.
Reconstitution steps (standard sterile protocol):
1. Wipe vial tops with alcohol.
2. Draw 2.0 mL bacteriostatic water (two full U-100 syringes to the 100-unit mark).
3. Slowly inject into the 5 mg vial along the side wall.
4. Gently swirl (do not shake) until fully dissolved (~20 minutes).
5. Refrigerate; stable for ~28 days.
Subcutaneous injection protocol (research use only, once-weekly):
• Use a fresh U-100 (or 0.3–1 mL) insulin syringe with 27–31G needle.
• Sites: abdomen, thigh, upper arm, or flank (rotate sites).
• Pinch skin, insert at 45–90°, inject slowly, hold 5–10 seconds, withdraw.
• For non-human/lab animal use, scale dose by body weight (typical preclinical rodent doses ~3–300 nmol/kg SC; human-equivalent research doses below are for reference only).
Average/maintenance dose in research contexts → 2.4 mg once weekly (96 units on U-100). Titrate slowly over 8–16 weeks to minimize GI side effects (nausea, etc.).
This is strictly for laboratory/research investigation. Cagrilintide is not FDA-approved for human use.